TP53 and non-small cell lung carcinoma: This prompted several groups to develop a mouse model of NSCLC through global inactivation of p53 and activation of Kras (G12D mutation) in the lung epithelium, which was achieved via intrabronchial injection of adenoviral Cre [16]–[18].